![Ronald Stafford Watts](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ronald Stafford Watts
Directeur/Membre du Conseil chez Wenkart Foundation
Postes actifs de Ronald Stafford Watts
Sociétés | Poste | Début | Fin |
---|---|---|---|
Wenkart Foundation | Directeur/Membre du Conseil | - | - |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Ronald Stafford Watts
Anciens postes connus de Ronald Stafford Watts
Sociétés | Poste | Début | Fin |
---|---|---|---|
ENERGY ACTION LIMITED | Directeur/Membre du Conseil | 12/11/2015 | 30/06/2017 |
Président | 14/10/2011 | 12/11/2015 | |
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Directeur/Membre du Conseil | - | - |
Formation de Ronald Stafford Watts
The University of New South Wales | Undergraduate Degree |
University of Cambridge | Doctorate Degree |
Statistiques
Internationale
Australie | 5 |
Royaume-Uni | 3 |
Opérationnelle
Director/Board Member | 4 |
Chairman | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ENERGY ACTION LIMITED | Commercial Services |
Entreprise privées | 3 |
---|---|
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Health Technology |
Wenkart Foundation | |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |
- Bourse
- Insiders
- Ronald Stafford Watts
- Expérience